嵌合抗原受体T细胞治疗自身免疫性疾病
综述指出自身免疫病目前主要依赖广泛免疫抑制剂和阻断抗体治疗,常不能治愈,亟需先进疗法。工程化嵌合抗原受体(CAR)T细胞在肿瘤治疗成功后,可能成为部分自身免疫病的治疗选择。文章综述了抗CD19和抗B细胞成熟抗原CAR T细胞在系统性红斑狼疮、难治性抗合成酶综合征和重症肌无力中的首批临床结果,并讨论了临床前自身抗体受体T细胞、调节性CAR T细胞及安全性、制造和mRNA技术等议题。
要点
- 抗CD19 CAR T细胞已用于系统性红斑狼疮和难治性抗合成酶综合征的首批临床结果。
- 抗B细胞成熟抗原CAR T细胞已用于重症肌无力的首批临床结果。
- 临床前研究开发了可消除产生特定自身抗体B细胞克隆的嵌合自身抗体受体T细胞。
核心结论
- CAR T细胞可能成为部分自身免疫病的治疗选择,但综述未给出治愈性结论。
研究设计与样本
- 综述,检索范围未在原文中报告。
主要发现
- 抗CD19和抗B细胞成熟抗原CAR T细胞分别在系统性红斑狼疮、难治性抗合成酶综合征和重症肌无力中报告了首批临床结果。
- 临床前模型开发了可消除产生特定自身抗体B细胞克隆的嵌合自身抗体受体T细胞。
- 临床前模型开发了不消除自身反应性免疫细胞但抑制其错误激活的调节性CAR T细胞。
关键数值与推荐
- 原文未报告具体疗效数值或推荐条款。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune disorders occur when immune cells go wrong and attack the body's own tissues. Currently, autoimmune disorders are largely treated by broad immunosuppressive agents and blocking antibodies, which can manage the diseases but often are not curative. Thus, there is an urgent need for advanced therapies for patients suffering from severe and refractory autoimmune diseases, and researchers have considered cell therapy as potentially curative approach for several decades. In the wake of its success in cancer therapy, adoptive transfer of engineered T cells modified with chimeric antigen receptors (CAR) for target recognition could now become a therapeutic option for some autoimmune diseases. Here, we review the ongoing developments with CAR T cells in the field of autoimmune disorders. We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T cells for B cell elimination in systemic lupus erythematosus, refractory antisynthetase syndrome and myasthenia gravis, respectively. Furthermore, in preclinical models, researchers have also developed chimeric autoantibody receptor T cells that can eliminate individual B cell clones producing specific autoantibodies, and regulatory CAR T cells that do not eliminate autoreactive immune cells but dampen their wrong activation. Finally, we will address safety and manufacturing aspects for CAR T cells and discuss mRNA technologies and automation concepts for ensuring the future availability of safe and efficient CAR T cell products.
引用
- Blache U, Tretbar S, Koehl U, et al. CAR T cells for treating autoimmune diseases. RMD Open. 2023. PMID: 37996128. doi:10.1136/rmdopen-2022-002907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。